Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-08-23

Clinical Trial Update: Safety of SPD465 in Treating Adults With ADHD. [Phase 3]

View source ↗

Summary

Phase 3 trial update on SPD465 (attention-deficit/hyperactivity disorder) assessing safety in adults; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SPD465

Snippet

Sponsor: Shire | Conditions: Attention Deficit Disorder With Hyperactivity | Phase 3 | Status: COMPLETED